JP3141071B2 - Senso's side effect reducer - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an agent for reducing side effects of senso, comprising epimedium or its extract as an active ingredient.

[0002]

2. Description of the Related Art Epimedium has been strong since ancient times.
It is a crude drug that is used frequently for the purpose of strong energy. On the other hand, senso is a crude drug that has been used frequently for the purpose of instinct, its active ingredient is an inotropic steroid, and its main component is bufalin. In addition, the product exhibits excellent cardiotonic effects and relatively strong side effects such as arrhythmia, vomiting, discomfort, and convulsions, and these effects are also based on the cardiotonic steroids. The present inventors have conducted intensive studies to find a drug that reduces the side effects of Senso, and as a result, completed the present invention.

[0003]

DETAILED DESCRIPTION OF THE INVENTION The present invention relates to an agent for reducing side effects of senso, comprising epimedium or its extract as an active ingredient. As the extract of Epimedium, water, hot water, ethanol, aqueous ethanol and the like are used for extraction with a solvent usually used for extracting crude drug extracts, and then the solvent is removed by a method such as freeze-drying, spray-drying, and distillation under reduced pressure. The resulting powder can be used.

Epimedium or its extract can be used as a dry powder as it is, and this powder is usually used in various preparations such as tablets, granules,
What is formulated in a capsule, liquid or the like may be orally administered. Senso, on the other hand, may be orally administered to various formulations using known formulation techniques, for example, tablets, capsules, pills and the like, and the dosage is 0.5 mg.
In the range of ５5 mg. The dose of Epimedium or its extract for reducing the side effects of Senso is appropriately determined according to the dose of Senso, and when the dose of Senso is as described above, the dose of Epimedium is in the range of 1 mg to 100 mg. Is in the range of 0.5 mg to 50 mg. Epimedium or its extract may be administered at the same time as the administration of Senso, or may be administered 2-3 hours after that, but usually simultaneous administration is preferred in terms of simplicity. May be administered simultaneously, or epidermal or its extract and senso may be administered together with various preparations using known preparation techniques, for example, tablets, capsules, pills and the like. .

[0005]

The cardiotonic steroid, which is an active ingredient of senso, is a drug with a narrow safety margin, shows a cardiotonic action immediately after administration of senso, and has side effects accompanying it. Therefore, without affecting the absorption of cardiotonic steroids, to promote its excretion and metabolism so that it does not remain in the body,
It is important in reducing the side effects of this steroid. Epimedium and its extract according to the present invention, when administered orally at the same time as Senso, were able to promote the metabolism and excretion of cardiotonic steroids related to the side effects of Senso, and also to reduce the side effects of Senso. Therefore, epimedium and its extract according to the present invention are excellent as agents for reducing side effects of senso. Hereinafter, the present invention will be further described with reference to Examples, but the present invention is not limited thereto.

[0006]

【Example】

1) Experimental materials Test drug Senso (produced in Shandong, China) was used by pulverizing a dry mass. Epimedium (Yellow-flowered Epimedium Toyama) crushes the leaves of the dried product and 55% ethanol (100 ° C, 5 hours)
The material extracted in step was used. The pulverized product of Senso was sufficiently swelled in water and ultrasonically treated to obtain a homogeneous liquid, which was used as a drug solution for administration. The drug solution for administration was prepared as 4 mg / ml as Senso. The mixed chemical solution of Senso and Epimedium was prepared by dissolving Epimedium extract with Senso chemical solution. (4 mg / ml as Senso and 8 mg / ml as Epimedium)

[0007] 2. Experimental animal Wistar male rat (weight 160-180g)
Was purchased from Sankyo Lab Service Co., Ltd., and preliminarily reared before use in experiments.

2) Experimental method Quantification of bufosteroid in blood To 1 ml of rat serum, 4 ml of a mixture of hexane and chloroform (4: 1) was added and shaken for 10 minutes.
Centrifuge at 00 rpm and accurately collect 3.6 ml of the organic layer. The obtained organic layer is distilled off under reduced pressure to obtain a residue. This was dissolved in 100 μl of an internal standard solution ^{* to} obtain a sample solution.
Quantification was performed on 40 μl of this sample solution by high performance liquid chromatography (hereinafter, HPLC). The HPLC conditions are shown below. HPLC conditions Mobile phase; water: acetonitrile (1: 1) Flow rate: 1 ml / min Column: Wakosil 5C18N 4.6 mm × 15 cm 5 μm 40
C Detector: UV 300 nm * Internal standard solution 50% ethanol solution of n-hexyl p-hydroxybenzoate

3) Experimental results

[Table 1]

From the above results, the half-life of bufalin in blood in the group receiving senso was 1.3 hours, whereas that in the group receiving [senso + epimedium] was 0.91.
It was time. Therefore, it was confirmed that Epimedium has an excellent metabolism and excretion promoting effect on bufalin in Senso.

Claims (1)

(57) [Claims] 1. An agent for reducing side effects of senso, comprising epimedium or its extract as an active ingredient.